Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
The documentation for primary cutaneous T-cell lymphoma is limited primarily due to its rarity, affecting fewer than 5 in 10,000 people. This rarity results in fewer systematic clinical studies and a lack of comprehensive data on genetic factors and clinical features. As research continues, it is hopeful that more information will emerge to better characterize this condition.
To navigate your care for primary cutaneous T-cell lymphoma, consider seeking a hematologist or oncologist with specific expertise in lymphomas, particularly those focusing on cutaneous forms. Engaging with clinical trials may provide access to innovative treatments; you can find ongoing trials through the ClinicalTrials.gov link provided above. While there are currently no identified patient organizations, resources such as GARD (rarediseases.info.nih.gov) can offer valuable information and support. If you have questions about your treatment options, consider reaching out to a genetic counselor for personalized guidance.
There are currently 76 active clinical trials exploring various treatment options for primary cutaneous T-cell lymphoma. Among the orphan drugs designated for this condition are Bexarotene and denileukin diftitox-cxdl, which have received FDA approval. Additionally, several drugs are in development, including Brentuximab vedotin and others targeting STAT3 degradation. For more information on ongoing trials, visit the ClinicalTrials.gov search page: https://clinicaltrials.gov/search?cond=primary%20cutaneous%20T-cell%20lymphoma.
Actionable guidance for navigating care for primary cutaneous T-cell lymphoma
To navigate your care for primary cutaneous T-cell lymphoma, consider seeking a hematologist or oncologist with specific expertise in lymphomas, particularly those focusing on cutaneous forms. Engaging with clinical trials may provide access to innovative treatments; you can find ongoing trials through the ClinicalTrials.gov link provided above. While there are currently no identified patient organizations, resources such as GARD (rarediseases.info.nih.gov) can offer valuable information and support. If you have questions about your treatment options, consider reaching out to a genetic counselor for personalized guidance.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 1 company has orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.